



INDOCO REMEDIES LTD

indoco remedies limited

INDOCO HOUSE, 166 C. S. T. ROAD, SANTACRUZ (EAST), MUMBAI - 400 098 (INDIA) • Website : www.indoco.com
PHONES : (91-22) 3386 1000 / 3386 1250 • FAX : (91-22) 2652 3067 / 2652 3976 • CIN : L85190MH1947PLC005913

January 30, 2015

To
The Listing Department
National Stock Exchange of India Ltd
Exchange Plaza
Bandra Kurla Complex
Bandra (East)
Mumbai 400 051

To
The Listing Department
Bombay Stock Exchange Limited
Floor 25, P. J. Towers,
Dalal Street,
Mumbai – 400 001

Dear Sirs,

Sub: Unaudited Financial Results for the third quarter ended 31st December 2014

It is hereby informed that, the Board of Directors at their meeting have approved and taken on record the unaudited financial results of the Company for the third quarter ended 31st December 2014.

A copy of the said unaudited results as required by Clause 41 of the Listing Agreement is enclosed herewith.

Thanking you,

Yours faithfully,
For Indoco Remedies Limited

Sunil D. Joshi
Company Secretary

INDOCO REMEDIES LIMITED

Regd. Office : Indoco House, 166, CST Road, Santacruz (East), Mumbai 400 098

Tel: +91-22-26541851/55 Fax: +91-22-26520787 Email compliance.officer@indoco.com

Web: www.indoco.com CIN: L85190MH1947PLC005913

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2014

PART - I

(₹ In Lacs)

Sr. No	Particulars	Quarter ended 31.12.2014 (Unaudited)	Quarter ended 30.09.2014 (Unaudited)	Quarter ended 31.12.2013 (Unaudited)	Nine month ended 31.12.2014 (Unaudited)	Nine month ended 31.12.2013 (Unaudited)	Year ended 31.03.2014 (Audited)
1	Income from Operations						
	(a) Gross Sales / Income from Operations	21,544	22,955	19,171	64,623	54,126	73,011
	(b) Excise Duty	(251)	(313)	(330)	(892)	(975)	(1,274)
	(c) Net Sales / Income from Operations (a-b)	21,293	22,642	18,841	63,731	53,151	71,737
	(d) Other Operating Income	373	201	(60)	642	1,258	1,034
	Total Income from Operations (Net) (c+d)	21,666	22,843	18,781	64,373	54,409	72,771
2	Expenses						
	(a) Cost of materials consumed	6,409	7,421	5,226	20,116	16,830	23,016
	(b) Purchases of stock-in-trade	1,252	1,574	905	3,974	3,195	4,005
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	107	(1,024)	1,109	(1,094)	760	(105)
	(d) Employee Benefits expense	3,471	3,596	3,223	10,440	9,445	12,905
	(e) Depreciation and Amortisation expense	1,198	1,315	802	3,460	2,307	3,091
	(f) Research & Development Expense	503	489	367	1,422	1,025	1,443
	(g) Other Expenses	5,655	5,924	4,966	16,725	14,433	19,500
	Total Expenses	18,595	19,295	16,598	55,043	47,995	63,855
3	Profit from Operations before Other Income, finance costs and Exceptional Items (1-2)	3,071	3,548	2,183	9,330	6,414	8,916
4	Other Income	20	56	11	137	73	175
5	Profit from ordinary activities before finance costs and Exceptional Items (3+4)	3,091	3,604	2,194	9,467	6,487	9,091
6	Finance Costs	271	268	386	813	1,535	1,880
7	Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	2,820	3,336	1,808	8,654	4,952	7,211
8	Exceptional Items	-	-	-	-	-	-
9	Profit from Ordinary activities before tax (7-8)	2,820	3,336	1,808	8,654	4,952	7,211
10	Tax Expenses	658	1,095	396	2,248	1,018	1,421
11	Net Profit from Ordinary activities after tax (9-10)	2,162	2,241	1,412	6,406	3,934	5,790
12	Extraordinary Items	-	-	-	-	-	-
13	Net Profit for the period (11-12)	2,162	2,241	1,412	6,406	3,934	5,790
14	Paid up Equity Share Capital (Face value ₹2/-each)	1,843	1,843	1,843	1,843	1,843	1,843
15	Reserves excluding Revaluation Reserves as per Balance Sheet of Previous accounting year						43,854
16	Earnings per share (before and after extraordinary items) (of ₹ 2/- each) (not annualised):						
	(a) Basic	2.35	2.43	1.53	6.95	4.27	6.28
	(b) Diluted	2.35	2.43	1.53	6.95	4.27	6.28

PART- II Select Information for the Quarter and nine months ended 31st December, 2014

Sr. No	Particulars	Quarter ended 31.12.2014 (Unaudited)	Quarter ended 30.09.2014 (Unaudited)	Quarter ended 31.12.2013 (Unaudited)	Nine month ended 31.12.2014 (Unaudited)	Nine month ended 31.12.2013 (Unaudited)	Year ended 31.03.2014 (Audited)
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding						
	- Number of Shares	375,51,521	375,52,721	375,78,444	375,51,521	375,78,444	376,01,399
	- Percentage of Shareholding	40.75	40.75	40.78	40.75	40.78	40.80
2	Promoters and promoter group shareholding						
	a) Pledged/Encumbered						
	- Number of shares	-	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of shares	545,98,834	545,97,634	545,71,911	545,98,834	545,71,911	545,48,956
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	59.25	59.25	59.22	59.25	59.22	59.20

Sr. No	Particulars	3 months ended 31.12.2014	
B	INVESTOR COMPLAINTS		
	Pending at the beginning of the quarter	Nil	
	Received during the quarter	4	
	Disposed of during the quarter	4	
	Remaining unresolved at the end of the quarter	Nil	

Notes :

- 1 The company has only one primary reportable segment of activity, namely, Pharmaceuticals.

Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:

(₹ In Lacs)

Net Sales and Income from Operations	Quarter ended 31.12.2014 (Unaudited)	Quarter ended 30.09.2014 (Unaudited)	Quarter ended 31.12.2013 (Unaudited)	Nine month ended 31.12.2014 (Unaudited)	Nine month ended 31.12.2013 (Unaudited)	Year ended 31.03.2014 (Audited)
India	12,965	14,469	12,067	40,235	35,227	46,302
Outside India	8,328	8,173	6,774	23,496	17,924	25,435
Total	21,293	22,642	18,841	63,731	53,151	71,737

- 2 The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 30th January, 2015.
- 3 The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 31st December, 2014.
- 4 The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.

By Order of the Board
For Indoco Remedies Ltd

Suresh G. Kare
Chairman

Place : Mumbai
Date : 30th January, 2015